Submission to First Editorial Decision (Median Days): 7
Submission to First Decision with Peer Review (Median Days): 28.1
Submission to Accept (Median Days): 86.1
Accept to ASAP Publication (Median Days): 14.3

Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

Some specific areas that are appropriate include the following:

Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools.
Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be accepted for publication.
Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds.
Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition.
Computational studies that provide fresh insight into the SAR of compound series that are of current general interest or analysis of other available data that subsequently advance medicinal chemistry knowledge.
Substantially novel computational chemistry methods with demonstrated value for the identification, optimization, or target interaction analysis of bioactive molecules.
Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs.
Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules.

Articles
Brief Articles
Perspectives
Drug Annotations
Viewpoint
Featured Articles

Editors
Gunda I. Georg
Department of Medicinal Chemistry
College of Pharmacy
University of Minnesota
Editor's Office: (612) 624-6184
E-mail: georg-office@jmedchem.acs.org
Shaomeng Wang
University of Michigan Comprehensive Cancer Center
University of Michigan
Editor's Office: (734) 615-2399
E-mail: wang-office@jmedchem.acs.org

Managing Editor
Lorraine Clark
E-mail: l_clark@acs.org

Associate Editors
Jürgen Bajorath
University of Bonn
E-mail: bajorath-office@jmedchem.acs.org
Brian S. J. Blagg
University of Notre Dame
E-mail: blagg-office@jmedchem.acs.org
Maria Laura Bolognesi
University of Bologna
E-mail: bolognesi-office@jmedchem.acs.org
Stuart Conway
University of Oxford
E-mail: conway-office@jmedchem.acs.org
Mark Cushman
Purdue University
E-mail: cushman-office@jmedchem.acs.org
William Denny
University of Auckland
E-mail: denny-office@jmedchem.acs.org
Ke Ding
Jinan University
E-mail: ding-office@jmedchem.acs.org
Carrie Haskell-Luevano
University of Minnesota
E-Mail: carrie@jmedchem.acs.org
Ulrike Holzgrabe
University of Würzburg
E-mail: holzgrabe-office@jmedchem.acs.org
Hualiang Jiang
Shanghai Institute of Materia Medica
E-mail: jiang-office@jmedchem.acs.org
Nouri Neamati
University of Michigan
E-mail: neamati-office@jmedchem.acs.org

Perspectives Editor
Nicholas Meanwell
Bristol-Myers Squibb
E-mail: meanwell-office@jmedchem.acs.org
Drug Annotations Editors
Carlos Garcia-Echeverria
Sanofi
E-mail: echeverria-office@jmedchem.acs.org
Jeff Zablocki
Pharmacyclics LLC
E-mail: zablocki-office@jmedchem.acs.org
Editor Emeritus
Philip S. Portoghese
University of Minnesota